Jodie Chang1, Resmi Charalel2, Christopher Noda1, Raja Ramaswamy1, Seung Kwon Kim1,3, Michael Darcy1,3, Gretchen Foltz1, Olaguoke Akinwande4,3. 1. Division of Interventional Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine in St. Louis, St. Louis, MO, U.S.A. 2. Division of Interventional Radiology, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY, U.S.A. 3. Siteman Cancer Center at Washington University in St. Louis, St. Louis, MO, U.S.A. 4. Division of Interventional Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine in St. Louis, St. Louis, MO, U.S.A. oakinwa@wustl.edu.
Abstract
AIM: To compare toxicity, response, and survival outcomes of patients with hepatic metastases from breast cancer who underwent transarterial chemoembolization (TACE) or radioembolization (TARE). MATERIALS AND METHODS: A retrospective review was carried out of all patients who underwent TACE or TARE for liver-dominant breast cancer metastases between January 2006 and March 2016 at an academic medical center in the United States. RESULTS: Seventeen patients in the TACE group and 30 patients in the TARE group received 32 TACE and 49 TARE treatments, respectively. Median follow-up was 9 months. Both groups had similar background variables. More all-grade adverse events were seen in the TACE group (71% vs. 44%; p=0.02). Median overall survival in the TACE group was 4.6 months compared to 12.9 months in the TARE group (p=0.2349). Treatment type was not an independent prognostic factor. CONCLUSION: TARE is better tolerated than TACE for the treatment of liver-dominant breast cancer metastasis. There was a trend towards improved survival with TARE; however, it did not approach statistical significance. Larger studies are needed to validate these findings. Copyright
AIM: To compare toxicity, response, and survival outcomes of patients with hepatic metastases from breast cancer who underwent transarterial chemoembolization (TACE) or radioembolization (TARE). MATERIALS AND METHODS: A retrospective review was carried out of all patients who underwent TACE or TARE for liver-dominant breast cancer metastases between January 2006 and March 2016 at an academic medical center in the United States. RESULTS: Seventeen patients in the TACE group and 30 patients in the TARE group received 32 TACE and 49 TARE treatments, respectively. Median follow-up was 9 months. Both groups had similar background variables. More all-grade adverse events were seen in the TACE group (71% vs. 44%; p=0.02). Median overall survival in the TACE group was 4.6 months compared to 12.9 months in the TARE group (p=0.2349). Treatment type was not an independent prognostic factor. CONCLUSION:TARE is better tolerated than TACE for the treatment of liver-dominant breast cancer metastasis. There was a trend towards improved survival with TARE; however, it did not approach statistical significance. Larger studies are needed to validate these findings. Copyright
Authors: B M Aarts; F M Gómez Muñoz; H Wildiers; V O Dezentjé; T R Baetens; W Schats; M Lopez-Yurda; R C Dresen; B J de Wit-van der Veen; C M Deroose; G Maleux; R G H Beets-Tan; E G Klompenhouwer Journal: Cardiovasc Intervent Radiol Date: 2021-07-28 Impact factor: 2.740
Authors: Eduardo A Lacayo; Sara Velayati; Ahmed Elsakka; Lynn Brody; Joseph P Erinjeri; Etay Ziv; Franz E Boas; Constantinos T Sofocleous; Mikhail Silk; Vicky Makker; William P Tew; Hooman Yarmohammadi Journal: J Vasc Interv Radiol Date: 2021-02-23 Impact factor: 3.682
Authors: Elie Barakat; Andras Bibok; Anupam Rishi; Altan Ahmed; Jessica M Frakes; Sarah E Hoffe; Avan J Armaghani; Aixa E Soyano; Ricardo L B Costa; Ghassan El-Haddad; Junsung Choi; Bela Kis Journal: Adv Radiat Oncol Date: 2021-10-29